Human breast cancer cell lines expressing the estrogen receptor a (ERa), all-trans-retinoic acid (ATRA) receptor a (RARa) and cellular retinoic acid binding protein II (CRABPII) genes are sensitive to ATRA-mediated growth inhibition. To study the relationship among ERa, RARa and CRABPII expression, the protein levels of each member were compared in five breast cancer cell lines (T47D, MCF-7, ZR-75-1, Hs587 T and MDA-MB-231 cells) and two immortalized nontumorigenic breast epithelial cell lines (MTSV1.7 and MCF-10A). ERa, RARa and CRABPII proteins were detected in T47D, MCF-7 and ZR-75-1 cells but not in other tested cell lines. RARa and CRABPII proteins were either reduced or undetectable in T47D/C4:2W and MCF-7/ADR cells with lost expression of ERa. Estradiol increased and antiestrogens (tamoxifen and ICI 164,384) downregulated the expression of both RARa and CRABPII proteins in T47D and MCF-7 cells. RARa antagonist Ro-41-5253 inhibited CRABPII expression, but not RARa expression in estradiol-treated T47D and MCF-7 cells. Suppression of ERa by small interfering RNA (siRNA) reduced RARa and CRABPII gene expression and siRNA suppression of RARa reduced CRABPII expression while having no effect on ERa in T47D cells. Transient transfection of either RARa or ERa expression vectors increased CRABPII expression in MDA-MB-231 cells but only RARa, not ERa, activated hCRABPII promoter reporter. These results indicate that there is a gene activation pathway in which ERa drives RARa transcription and RARa drives CRABPII transcription in ERa-positive human breast cancer cells.
Introduction
All-trans-retinoic acid (ATRA), a metabolite of vitamin A, is an essential physiological regulator of vertebrate embryonic development and adult tissue homeostasis (Ross and Ternus, 1993; Chambon, 1996) . ATRA has been successfully used to induce clinical remission in acute promyelocytic leukemia patients (Huang et al., 1988; Warrell et al., 1991; Degos et al., 1995; Tallman et al., 2002) and retinoids are of therapeutic interest in breast cancer because of their efficacy in preventing carcinogen-induced rat mammary cancers (Anzano et al., 1994; Gottardis et al., 1996) , and their antiproliferative effect toward breast cancer cells in vitro (Seewaldt et al., 1995; Zhao et al., 1995; Fitzgerald et al., 1997; Van heusden et al., 1998; Niles, 2000; Yang et al., 2002) . The effects of ATRA are mainly mediated by two classes of proteins, cellular retinoic acid binding proteins (CRABPs) and nuclear receptors (Chambon, 1996) . There are two known CRABPs, CRABPI and CRAB-PII, which contribute to ATRA signaling by virtue of their ability to sequester and alter the metabolism of ATRA (Ong et al., 1994) . CRABPII has been proposed to function as a transcriptional coactivator (Delva et al., 1999) and, more recently, as a chaperone that facilitates ATRA transport to the nucleus (Noy, 2000) . The nuclear receptors mediating the gene regulatory effects of ATRA are the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs), which function as liganddependent, transcription heterodimers (Mangelsdorf et al., 1994; Chambon, 1996) .
Estrogen receptor a (ERa) positive breast cancer cells, relative to ERa-negative breast cancer cells, have been found to have increased sensitivity to ATRA-mediated growth inhibition (Fontana, 1987; van der Leede et al., 1995) . Surveys of RAR expression in breast cancer cells have shown that while RARg was more or less uniformly expressed, RARa was underexpressed in cells resistant to growth inhibition by ATRA as compared to sensitive cells (Roman et al., 1992; Sheikh et al., 1993; van der Burg et al., 1993; Fitzgerald et al., 1997) . Studies of retinoids capable of discriminating among RAR subtypes have confirmed that RARa is a critical mediator of the antiproliferative effect of ATRA in breast cancer cells (Dawson et al., 1995) . The association of ATRA resistance with the lack of ERa expression and low RARa abundance led to investigations of the relationship between ERa and RARa expression. ERa has been shown to be a direct regulator of RARa transcription and an estrogen response element (ERE) was identified in the RARa promoter (Roman et al., 1993; Rishi et al., 1995; van der Leede et al., 1995; Han et al., 1997) . We have reported that CRABPII is also highly expressed or induced in ATRA-sensitive breast cancer cells (Jing et al., 1997) , and we and others have shown that ectopic CRABPII enhanced ATRA action in breast cancer cells (Jing et al., 1997; Manor et al., 2003) . Human CRABPII transcription is under direct positive regulation by RAR and typical RAREs have been identified in its promoter (Astrom et al., 1992; Tavakkol et al., 1992) . The fact that ERa, RARa and CRABPII are expressed in human breast cancer cells that are sensitive to ATRA growth inhibition implies that these genes may be coregulated. Here we investigate the relationship among ERa, RARa and CRABPII expression in human breast cancer cells and provide multiple lines of evidence for the existence of a linear gene activation cascade flowing from ERa to RARa to CRABPII in this order.
Results

CRABPII expression is correlated with RARa and ERa expression in a panel of breast cell lines
ERa, RARa and CRABPII protein levels were compared in five human breast cancer cell lines (T47D, MCF-7, ZR-75-1, Hs587T and MDA-MB-231) and two immortalized human breast epithelial cell lines (MTSV1.7 and MCF-10A) by Western blot analysis. As shown in Figure 1 , ERa protein was detected in T47D, MCF-7 and ZR-75-1 cells, but was not detectable in other tested cell lines. Correlating with ERa expression, RARa protein was detected in T47D, MCF-7 and ZR-75-1 cells but not detectable in other tested cell lines. These data are consistent with previous reports that RARa is an ERa target gene and that ERa-positive breast cancer cells express abundant RARa (van der Leede et al., 1995) . Similar to ERa and RARa expression, CRABPII protein was also detected in T47D, MCF-7 and ZR-75-1 cells but not in other tested cell lines. These data suggest that CRABPII expression may be regulated by either ERa or RARa or both receptors in T47D, MCF-7 and ZR-75-1 cells.
RARa and CRABPII expression is reduced in ERa-negative T47D and MCF-7 cell variants or in parental cells treated with antiestrogens Both MCF-7/Adr cells, a subclone of MCF-7 cells, and T47D/C4:2W cells, a subclone of T47D cells, have been shown to have reduced level of ERa mRNA and protein (Pink et al., 1996; Lin and Nelson, 2003) . To test whether ERa drives RARa and CRABPII expression, ERa, RARa and CRABPII protein levels were tested in these two cell lines. As shown in Figure 2 , T47D/C4:2W and MCF-7/Adr cells had no detectable ERa protein.
The protein levels of RARa and CRABPII were significantly decreased in T47D/C4:2W cells and were undetectable in MCF-7/Adr cells. T47D cells were treated with the antiestrogen ICI 164,384, and the mRNA and protein levels of RARa and CRABPII were measured by Northern and Western blot analyses. Treatment (24 h) of T47D cells cultured in phenol red free and 10% CT-FCS (which was used to decrease the endogenous levels of estrogen) with 10 nM ICI 164,384 resulted in decreases in both RARa and CRABPII expression at the mRNA ( Figure 2b ) and protein levels ( Figure 2c ). To further confirm the effect of ERa on RARa and CRABPII expression, both MCF-7 and T47D cells were treated with another antiestrogen, tamoxifen. The protein levels of both RARa and CRABPII were decreased to nearly undetectable levels after 48 h treatment with tamoxifen at 10 nM ( Figure 2d ). These data suggest that ERa might control both RARa and CRABPII expression in human breast cancer cells.
Estradiol increases both RARa and CRABPII expression in T47D cells
Treatment of T47D cells with estradiol resulted in an increase in RARa and CRABPII protein levels ( Figure 3a) . To test whether ERa increases RARa and CRABPII proteins through an RARa activationmediated pathway, RARa antagonist Ro-41-5253 (Apfel et al., 1992) was used. Treatment of T47D or MCF-7 cells with Ro-41-5253 decreased CRABPII alone and blocked estrogen-upregulated CRABPII protein levels in cotreatment. However, RARa protein upregulation by estradiol treatment was not blocked by addition of Ro-41-5253. Interestingly, RARa protein level was increased by Ro-41-5253 treatment. Ro 41-5253 had a dose-dependent inhibitory effect on CRABPII mRNA and protein levels in T47D cells (Figures 3b and c) . These data suggest an ERa to RARa to CRABPII gene regulatory cascade in human breast cancer cells. Figure 4c with a). The ERa, RARa and CRABPII protein levels were also measured by quantitative Western blot analysis. As shown in Figure 4d , the protein levels of ERa, RARa and CRABPII were decreased in ERa siRNA-treated T47D cells. The protein levels of RARa and CRABPII, but not ERa, were decreased in RARa siRNA-treated T47D cells. The results generated from Western blot analysis are consistent with that of immunocytochemical studies. These data further suggest that ERa regulates RARa expression and RARa in turn regulates CRABPII expression in T47D cells. proteins were detected in these cells. These data are consistent with the previous report that RARa protein was not restored in S30 cells (Rosenauer et al., 1998) . Moreover, it has been found that normal ERa function was not restored since estradiol induced apoptosis instead of growth stimulation in these cells (Rosenauer et al., 1998) . In an attempt to drive RARa expression in MDA-MB-231 cells, we transiently transfected ERa and achieved higher ERa protein levels than in S30 cells ( Figure 5 ), and both RARa and CRABPII protein expression could now be detected. When MDA-MB-231 cells were transiently transfected with RARa, higher levels of CRABPII protein were obtained than in ERatransfected cells. To further confirm that RAR signaling was intact in S30 cells, RARa was transiently transfected into S30 cells, and CRABPII protein was detectable ( Figure 5 ). These data suggest that S30 cells behave differently from breast cancer cells expressing endogenous ERa and support the hypothesis that ERa upregulates CRABPII through RARa induction.
Transient transfection of
CRABPII promoter is activated by ATRA but not by estradiol
The CRABPII promoter has been shown to contain RAREs and could be activated by ATRA in a transient transfection system (Astrom et al., 1992) . To test the effect of RARa and ERa on CRABPII promoter activation, CRABPII-pGL3-luc reporter was generated and cotransfected with RARa or ERa into COS-7 cells that were then treated with ATRA or estradiol, respectively. As shown in Figure 6 , ATRA increased the activity of the CRABPII promoter reporter after cotransfection of RARa and RARa plus RXRa. In contrast, estradiol did not activate the CRABPII promoter in cells cotransfected with ERa. These data 
indicate that expression of CRABPII is directly regulated by RARa signaling, not by ERa signaling, in human breast cancer cells.
Discussion
Cellular phenotypes are in great part controlled by transcriptional regulatory cascades and that involving ERa is of obvious significance to human breast cancer. ERa, RARa and CRABPII genes are coexpressed in human breast cells (Figure 1 ), suggesting that their expression, two of which are transcription factors, is coordinately regulated. It has been reported that ERa transcriptionally upregulates RARa expression (Roman et al., 1993; van der Leede et al., 1995; Rousseau et al., 2003) and RARa transcriptionally upregulates CRAB-PII expression (Astrom et al., 1992) , suggesting a simplest hypothesis that ERa to RARa to CRABPII cascade exists. However, recent reports demonstrated that, in rat uterine cells, estradiol directly upregulates, but ATRA does not, CRABPII transcription (Bucco et al., 1997; Li and Ong, 2003) , raising the prospect that ERa may independently regulate RARa and CRABPII expression.
Our data provide several lines of evidence in support of the hypothesis of an ERa to RARa to CRABPII gene activation cascade in human breast cancer cells. The first line of evidence is correlative and shows, for various cell models, that ERa expression is poorly associated with CRABPII expression unless RARa is also expressed (Figures 1, 2a and 5) . The second line of evidence is pharmacological and shows that (a) ERa inactivation is associated with the downregulation of both RARa and CRABPII expression in breast cancer cells ( Figure 2) ; (b) ERa activation upregulates both RARa and CRABPII, and the effect of ERa activation on CRABPII is blocked by RARa antagonist (Figures 3a  and 5) ; and (c) RARa inhibition leads to strong CRABPII downregulation (Figure 3b and c) . The third line of evidence is based on a genetic loss-of-function approach and shows that ERa knockdown leads to downregulation of both RARa and CRABPII expression whereas RARa knockdown leads to CRABPII downregulation without any effect on ERa (Figure 4) . The fourth line of evidence is based on a genetic gain-offunction approach and shows that ectopic ERa upregulates both RARa and CRABPII expression in ERanegative MDA-MB-231 cells ( Figure 5 ). Ectopic RARa expression in the same cells does not affect ERa expression but upregulates CRABPII more strongly than in the presence of ectopic ERa ( Figure 5 ). Finally, functional CRABPII promoter analysis demonstrated that only RARa, not ERa activation, is capable of driving transcription of a CRABPII reporter construct ( Figure 6 ). Taken together, these experiments strongly suggest in favor of an obligatory sequence of events whereby ERa activates RARa and RARa activates CRABPII in human breast cancer cells. Species and perhaps tissue-specific differences may account for the divergence between our results and those for rat uterine cells (Astrom et al., 1992; Li and Ong, 2003) . This possibility is underscored by the apparent absence from the human CRABPII promoter of an ERE analogous to that identified in the rat CRABPII promoter (Li and Ong, 2003) . In mouse F9 cells, available genetic evidence implicates RARa as a main regulator of CRABPII transcription through a post-transcriptional pathway (MacGregor et al., 1992; Boylan et al., 1995; Di et al., 1998) .
Our conclusion that ERa, RARa and CRABPII form a linear gene activation cascade does not exclude the possibility that, under some conditions, RARa expression may be dissociated from ERa expression. Indeed, it is known that RARa is not exclusively dependent on ERa expression (Fitzgerald et al., 1997; Schneider et al., . Although most ERa-negative breast cancer cells do not express RARa, some ERa-negative breast cancer cell lines retain sufficient RARa expression to undergo ATRA-induced growth arrest (Fitzgerald et al., 1997; Nakagawa et al., 2003) and T47D C4:2W cells, while being devoid of ERa, still express some RARa (Figure 2) . Likewise, our conclusion does not exclude the possibility that, under some circumstances, CRAB-PII expression may be dissociated from RARa expression. A case in point is the ERa-negative MDA-MB-468 cell line, which expresses low RARa but high CRABPII mRNA levels (Guo et al., 2000) . In human keratinocytes, RARg has been shown to drive CRABPII expression (Astrom et al., 1992; Di et al., 1998) suggesting that in MDA-MB-468 cells, which express RARg (Widschwendter et al., 1995) , this receptor may account for CRABPII expression. However, MDA-MB-468 cells constitute an exception rather than the rule since RARa, not RARg, is the RAR isoform most consistently implicated in CRABPII induction (Figures 3-6) (Boylan et al., 1995; Pasquali et al., 1997; Widschwendter et al., 1997a, b; Di et al., 1998; Yang et al., 2002) . In summary, our work demonstrates that, typically, ERa-positive breast cells are characterized by the linear coexpression of RARa and then CRABPII and ERanegative breast cells lack or express low levels of both RARa and CRABPII. Because RARa has been strongly implicated in breast cancer cell growth inhibition (Dawson et al., 1995; Fitzgerald et al., 1997) and CRABPII has been implicated in the potentiation of this effect (Jing et al., 1997; Manor et al., 2003) , our data support early observations that ERa-positive breast cancer cells were more sensitive than ERa-negative breast cancer cells to ATRA treatment (Fontana, 1987; van der Leede et al., 1995) . Moreover, since ERa is highly expressed in ERa-positive breast cancer cells relative to normal immortalized breast epithelial cells (Figure 1 ), this suggests that ATRA treatment might selectively target ERa-positive breast cancer cells, but not normal breast epithelial cells.
Materials and methods
Cells and reagents
T47D, MCF-7, ZR-75-1, MDA-MB-231, and Hs587 T cells were obtained from ATCC (Rockville, MD, USA) and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 5 mg/ml insulin, 100 U/ml penicillin and 100 mg/ml streptomycin. Two immortalized nontumorigenic breast epithelial cell lines were used: MCF-10A (obtained from ATCC), grown as an adherent monolayer in normal calcium, and MTSV1.7, grown as described and kindly provided by Dr Joyce Taylor-Papadimitriou (Bartek et al., 1991) . T47DC4:2W, a T47D variant with defective ERa expression (Pink et al., 1996) , and S30 cells (Jiang et al., 1992; Pink et al., 1996) , a subclone of MDA-MB-231 with ectopic ERa expression, were kindly provided by Dr V Craig Jordan (Northwestern University, Chicago, IL, USA) and cultured in phenol-red-free RPMI 1640 medium supplemented with 10% charcoal-stripped FBS, 5 mg/ml insulin, 100 U/ml penicillin and 100 mg/ml streptomycin. Charcoal stripping of serum was carried out as follows: 1.25 g of activated charcoal and 0.125 g of dextran (both from Sigma, St Louis, MO, USA) were added to a 500 ml bottle of FBS, incubated at 551C for 30 min and centrifuged at 3000 r.p.m. for 20 min; the resulting single stripped serum was collected into a fresh 500 ml bottle and the procedure repeated but with incubation at 371C for 30 min, followed by centrifugation and filter sterilization of the doublestripped serum.
ATRA and estradiol were obtained from Sigma (St Louis, MO, USA). Ro-41-5253 and ICI 164,384 were kind gifts from Dr M Klaus (Hoffmann-La Roche) and Alan Wakeling (Zeneca).
Antibodies
Rabbit polyclonal antibodies to human RARa and ERa (Santa Cruz) were used for Western blot analysis. Rabbit polyclonal antibody to CRABPII was generated as follows. The specific CRABPII peptide EQTVDGRPC (Busch et al., 1990) was conjugated to keyhole limpet hemocyanin using mmaleimidobenzoyl-N-hydroxysuccinimide ester, and New Zealand white rabbits were injected subcutaneously with conjugated peptide in complete Freund's adjuvant. Booster injections were carried out biweekly using complete (first booster) or incomplete Freund's adjuvant, and antiserum collected after a total of four and six immunizations. The antiserum was purified by peptide affinity chromatography and tested at 1/200 dilution using T47D and MDA-MB-231 cell extracts as positive and negative controls for CRABPII expression, respectively (Jing et al., 1997) ; neither CRABPI (Jing et al., 1997) nor CRBPI (Jing et al., 1996) proteins are expressed in these cells. A single band of the expected size (15 kDa) was detected in T47D extracts but not in MDA-MB-231 extracts.
For immunocytochemistry, the CRABPII antibodies described above were used in conjunction with Alexa Fluor 488 goat anti-rabbit immunoglobulin G (IgG; Molecular Probes, Eugene, OR, USA). ERa and RARa were visualized using mouse monoclonal antibodies (obtained from Santa Cruz and Dr P Chambon, respectively) in conjunction with Alexa Fluor 568 goat anti-mouse IgG or with Alera Fluor 488 goat antimouse IgG.
Activation of CRABPII promoter in pGL3
A basic human CRABPII promoter (À1038 to þ 125) fragment was generated by PCR amplification of hCRAB-PII-pBLCAT (Astrom et al., 1991) , a gift from Dr John J Voorhees, followed by ligation into pGL3 basic vector at SacI and HindIII restriction sites. The PCR primers used (listed 5 0 -3 0 ) were C GAGCTC CTG CAG GAA GCC GTG CCC TCC TC (À1038/À1016) and CCC AAGCTT AGG CTG GAG CAC TGG ACA CTG TC ( þ 103/ þ 125). The CRABPII-driven Luc reporter construct was transiently cotransfected into COS-7 cells with or without pSG5-ERa, pSG5-RARa, or pSG5-RARa plus pSG5-RXRa expression vectors using Lipofectamine 2000 Reagents (Invitrogen); pCH110 (b-galactosidase reporter vector) was used as an internal transfection control. At 24 h after transfection, cells were treated with either 10 À6 M ATRA or 10 À8 M estradiol for another 48 h and lysed and assayed for luciferase activity using the luciferase reporter assay system (DLReasy Turner Designs). The data are presented as the luciferase/b-Gal activity ratio.
Transient transfection of RARa and ERa into MDA-MB231cells
MDA-MB-231 cells were plated in 10 cm plates and allowed to attach in serum-supplemented medium for 24 h. Cells at 60-80% confluence were transfected with pSG5, pSG5-RARa or pSG5-hERa expression as described above and harvested 48 h later by scraping, washed with PBS and lysed with RIPA buffer. The levels of ERa, RARa and CRABPII protein were tested by Western blot analysis as described below.
Small interference RNA transfection of ERa and RARa siRNA transfection was performed according to the GTS kit instruction manual (San Diego, CA, USA). Template DNAs for transcription were prepared by PCR with gene-specific PCR primers containing T7 RNA polymerase promoter site. Double-stranded RNAs (dsRNAs) were produced by T7 transcription reaction, and siRNAs were generated using recombinant Dicer Enzyme. The siRNAs were transfected into T47D cells by using GeneSilencer siRNA transfection reagents. The RNA sequences used as PCR primers (listed 5 0 to 3 0 with underline) were as follows:
Immunocytochemistry
The protein levels of ERa, RARa and CRABPII in T47D cells after transfection of siRNAs were tested by immunostaining with antibodies to RARa, ERa and CRABPII. Briefly, T47D cells were fixed by 3.7% formaldehyde in PBS at room temperature for 15 min, and permeabilized with cooled acetic acid/ethanol (1 : 2) for 5 min at À201C, followed by incubation with appropriate blocking serum to reduce the background staining. The cells were incubated with primary antibodies against RARa, ERa or CRABPII overnight at 41C and second antibodies for 2 h at room temperature and were photographed using a Nikon Eclipse E600 microscope.
Western blot analysis
Protein extracts (50 mg) prepared with RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% NP-40, 0.5% sodium deoxycholate, 1 mM phenylmethyl sulfonyl fluoride, 100 mM leupeptin, and 2 mg/ml aprotinin, pH 8.0) were separated on 12% SDS-polyacrylamide gels and transferred to Protran BA83, 0.2 mm nitrocellulose membranes (Schleicher and Schuell, Keene, NH, USA). ERa, RARa and CRABPII proteins were visualized using the antibodies described above and ECL Western blotting reagents from Amersham LifeScience (Arlington Heights, IL, USA).
Northern Blot analysis
Total RNA was isolated from B2 Â 10 6 cells with Purescript reagents (Gentra Systems, Minneapolis, MN, USA). RNA (20 mg) was size-fractionated on a 1.2% agarose-2.2 M formaldehyde gel, transferred to Hybond-N þ nylon membrane (Amersham LifeScience, Arlington Heights, IL, USA) in 20 Â SSC, and UV-crosslinked (UV Stratalinker 2400, Stratagene, La Jolla, CA, USA). Full-length cDNAs for human RARa and human CRABPII were kindly provided by Dr P Chambon (IGBMC, Strasbourg, France) and Dr JJ Voorhees (University of Michigan Medical Center), respectively. A 316 bp human GAPDH cDNA fragment was obtained from Ambion (Austin, TX, USA). The probes were labeled with [a-32 P]dCTP by random priming to a specific activity of 10 9 cpm/mg. The membranes were prehybridized for 4 h at 421C in 50% formamide, 6 Â SSPE, 5 Â Denhardt's reagent and 0.2 mg/ml salmon sperm DNA, and hybridized overnight with radiolabeled probes. Blots were washed twice at room temperature and once at 651C before autoradiography.
